US 11,891,427 B2
Amidated peptides and their deamidated counterparts displayed by non-HLA-a*02 for use in immunotherapy against different types of cancers
Jens Hukelmann, Tuebingen (DE); Heiko Schuster, Tuebingen (DE); Lena Wullkopf, Tuebingen (DE); Christoph Schraeder, Tuebingen (DE); Jens Fritsche, Tuebingen (DE); Daniel Johannes Kowalewski, Tuebingen (DE); Michael Roemer, Tuebingen (DE); and Oliver Schoor, Tuebingen (DE)
Assigned to IMMATICS BIOTECHNOLOGIES GMBH, Tuebingen (DE)
Filed by Immatics Biotechnologies GmbH, Tuebingen (DE)
Filed on Sep. 29, 2021, as Appl. No. 17/489,446.
Claims priority of provisional application 63/223,291, filed on Jul. 19, 2021.
Claims priority of provisional application 63/084,919, filed on Sep. 29, 2020.
Prior Publication US 2022/0098269 A1, Mar. 31, 2022
Int. Cl. C07K 14/725 (2006.01); A61K 35/17 (2015.01); C07K 14/74 (2006.01); C07K 16/28 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/7051 (2013.01) [A61K 35/17 (2013.01); C07K 14/70539 (2013.01); C07K 16/2833 (2013.01); A61K 38/00 (2013.01); C07K 2319/30 (2013.01)] 20 Claims
 
1. A peptide consisting of the amino acid sequence of IYLDRTLLTTI (SEQ ID NO: 56) in the form of a pharmaceutically acceptable salt.